-
Mr. Xie Songting joined Dibeer as project manager of Bioreactor Division
Time of Update: 2022-08-30
com Mr. Xie Songting joined Dibeer to better serve the commercial production scale bioreactor users Follow Dibier Bio to learn about the most reliable bioreactor technology Tel: 021-57640001 Official website: Email: l@parallel-bioreactor.
-
The world's first
Time of Update: 2022-05-26
It is a First-in-Class bispecific antibody that simultaneously targets tumor antigen B7H4 and T cell costimulatory molecule 4-1BB .
The unique tumor expression specificity and immunomodulatory activity of HBM7008 is expected to produce better efficacy in PD-L1-negative patients or patients who are resistant to PD-1/PD-L1 immunotherapy drugs .
-
Express | Open up a new model of targeted RNA, Janssen reached a cooperation of over 1 billion US dollars
Time of Update: 2022-03-02
On February 17, 2022, Remix Therapeutics announced an R&D collaboration with Janssen, a subsidiary of Johnson & Johnson, to use Remix's REMaster drug discovery platform to develop small molecule therapeutics that modulate RNA processing .
-
Drug Administration: A batch of Nanning Baolai medical equipment is being recalled
Time of Update: 2021-10-20
actively recalled the ultrasonic scalerNanning Baolai Medical Devices Co.
actively recalled the ultrasonic scalerNanning Baolai Medical Equipment Co.
produced its ultrasonic scaler (model/specification: P5L, batch number: P5L21022601, product numbers: 03210320, 03210321, 03210322, 03210323, 03210324, 03210325, 03210326, 03210327, 03210328, 03210329) for active recall .
-
WuXi Giant Nuo BCMA Targeted CAR-T Therapy Applied for Clinical Application
Time of Update: 2021-09-06
Today, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that WuXi Junuo's JWCAR129 (targeting BCMA chimeric antigen receptor T cell) clinical trial application has been accepted .
Screenshot source: CDE official website
-
The second in the country
Time of Update: 2021-07-31
Hisun won the first imitation According to the official website of CDE, a total of 5 companies have submitted applications for the listing of lurasidone hydrochloride tablets for generic drugs.
-
Nuocheng Jianhua will hold 2020 results conference call on March 29, 2021
Time of Update: 2021-07-24
Conference call information Nuocheng Jianhua will hold a conference call at 9:00 am on March 29th, Beijing time .
After the meeting, participants can visit the investor relations page of Nuocheng Jianhua's official website to listen to the replay online .
-
Junshi Bio-Treprimumab injection is approved for the treatment of urothelial cancer
Time of Update: 2021-07-11
He has been treated for unresectable or metastatic melanoma that has failed systemic treatment in the past, and has been recommended by the Chinese Society of Clinical Oncology (CSCO) Melanoma Diagnosis and Treatment Guidelines in 2019 and 2020 .
-
Hengrui's new indication for carrelizumab for injection will be approved soon
Time of Update: 2021-07-06
The indications to be approved this time are: combined cisplatin and gemcitabine for the first-line treatment of patients with locally recurring or metastatic nasopharyngeal carcinoma .
After approval, it will be the sixth indication approved for carrelizumab .
-
The detection rate of the new coronavirus mutation gene E484K in six Brazilian states exceeds 50
Time of Update: 2021-04-28
△Image source: Official website of the Brazilian Ministry of HealthAccording to data released by the Brazilian research agency Osvaldo Cruz Foundation on the 4th, among the eight Brazilian states that were sampled and analyzed, the results of 6 states showed that more than 50% of the patient samples have found mutations in the new coronavirus.
-
The Lead Gene completed 60 million yuan of A round of financing to develop gene therapy with original delivery technology
Time of Update: 2021-04-24
(hereinafter referred to as Bendao Gene), a gene therapy development company with original delivery technology, completed a round A financing of 60 million yuan, led by Huakong Fund, Enran Venture Capital, Longmen Capital, ETP Fund, Inno Angel Fund and many other institutions followed in the investment.
-
Zhuang classic paint: "O2O" mode to find customers to let you deal
Time of Update: 2021-02-20
Zhuang classic paint "O2O" mode, for you to open the whole network "deal customers" marketing new model!
find customers, let you deal Zhuang classic paint will be reasonable allocation of e-commerce orders, online customer resources offline transmission, so that you personally contact with customers, and strive for customer transactions.
-
Edit RNA Processing Development Innovative RNA Drug Synth completes $81 million round of A financing
Time of Update: 2020-12-22
small molecule drugs designed by the company can be therapeutically regulated throughout the body, with the potential to treat a variety of diseases, including cancer, central system diseases, rare diseases and so on.
Retrieved December 9, 2020, from [2] Remix Therapeutics Launches with $81 Million Financing to Develop Small Molecule Therapies Designed to Reprogram RNA Processing.
-
National Health And Wellness Commission: pay attention to the needs of patients reasonable use of hemp medicine
Time of Update: 2020-12-03
It is emphasized that hemp essence medicine is a drug that is subject to special management according to law in our country, and the administrative departments and medical institutions at all levels of health should attach great importance to the clinical application management of hemp essence medicine.
-
Shanghai, Zhejiang and other 15 provinces and cities of the third batch of national mining implementation date was determined
Time of Update: 2020-11-05
in addition, Shanghai and Sichuan Province also have new news: Shanghai issued "on the implementation of the third batch of national organizations of centralized procurement of drugs in the results of the work tips", the content shows that the third batch of national mining is expected to be formally implemented in Shanghai in mid-to-late November, requiring medical institutions to ensure priority procurement and use of selected drugs, in advance to do a good job in preparation for the hospital.
